glp-1 ra cardiovascular benefits Frontiers Cardiovascular benefits of glucagon-like peptide-1

0.5 cases per 1,000 patient-years)

Effect of Baseline Body Mass Index on Glycemic Control and Weight Change With Exenatide Monotherapy in Chinese Drug-Nave Type 2 Diabetic Patients

Developed by Korean dermatologists using cutting-edge biopharmaceutical research

Eighty-five percent of US GLP-1 drug consumers report major changes in their food and beverage preferences after starting the medications, says a new report from ingredients giant IFF

Sulphonylureas may be preferred when cost is a primary consideration and the patient can safely manage potential hypoglycaemia, whilst DPP-4 inhibitors suit patients where hypoglycaemia avoidance is paramount